News brief
On 2026/4/29, Xiniu Data reported that Shuyin Zhike completed Pre-A funding worth tens of millions of USD. Cabio Biological Industry Investment (Wuhan) Co., Ltd. led the round, with other investors including Guangdong Kangrong Pharmaceutical Co., Ltd., Shanghai Grand NeoBay Ceyuan Venture Investment Partnership (Limited Partnership), and Ganzhou Guohui Runxin Venture Capital Fund (Limited Partnership). The company provides AI drug discovery services.
Connected profiles
Explore
Sources · 0Sources & provenance
English text is maintained separately from the original record. Consult the original source before citing a fact.
No source links are available for this profile.
Original source text
Names may use phonetic renderings when no English name is supplied. The original wording is retained below.
2026年4月29日，据烯牛数据报道，数因智科完成Pre-A轮融资，金额数千万美元。投资方为嘉必优生物产业投资（武汉）有限公司领投、广东康容药业股份有限公司、上海大零号湾策源创业投资合伙企业（有限合伙）、赣州国惠润信创业投资基金（有限合伙）等。该公司为AI药物研发服务商。